The Economic Times

As Ozempic's active ingredient's patent expires today, India's fit for a health-lifestyle revolution

Novo Nordisk's India patent expiry today unlocks affordable semaglutide, set to transform diabetes and weight management. Local players are readying generic versions of Ozempic and Wegovy. This 'Ozempiconomy' will boost health and wellness, reshape lifestyle choices, and influence community dynamics. The market is projected for substantial expansion, presenting a major opportunity for various sectors.